Want to join the conversation?
Drugmaker $VRTX reported a narrower 4Q15 loss driven by product revenue from cystic fibrosis treating drugs Orkambi and Kalydeco. Net loss narrowed to $75.51MM or $0.31 per share from $176.66MM or $0.74 per share last year. Revenue grew to $417.94MM from $144.56MM. Non-GAAP EPS was $0.17 compared to loss of $0.55 per share a year ago.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)